The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats

Costanza Emanueli, Julie Chao, Domenico Regoli, Lee Chao, Aiguo Ni, Paolo Madeddu

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

1. We evaluated if the brain bradykinin (BK) B1 receptor is involved in the regulation of blood pressure (BP) in conscious rats. 2. Basal mean BP and HR were 115 ± 2 and 165 ± 3 mmHg and 345 ± 10 and 410 ± 14 beats min-1 in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR), respectively. Intracerebroventricular (i.c.v.) injection of 1 nmol B1 receptor agonist Lys-desArg9-BK significantly increased the BP of WKY and SHR by 7 ± 1 and 19 ± 2 mmHg, respectively. One nmol Sar[D-Phe8]-desArg9-BK, a kininase-resistant B1 agonist, increased the BP of WKY and SHR by 19 ± 2 and 17 ± 2 mmHg, respectively and reduced HR in both strains. 3. I.c.v. injection of 0.01 nmol B1 antagonists, LysLeu8-desArg9-BK or AcLys[D-βNal7,Ile8]-desArg9-BK (R715), significantly decreased mean BP in SHR (by 9 ± 2 mmHg the former and 14 ± 3 mmHg the latter compound), but not in WKY. In SHR, the BP response to R715 was associated to tachycardia. 4. I.c.v. Captopril, a kininase inhibitor, increased the BP of SHR, this response being partially prevented by i.c.v. R715 and reversed into a vasodepressor effect by R715 in combination with the B2 antagonist Icatibant. 5. I.c.v. antisense oligodeoxynucleotides (ODNs) targeted to the B1 receptor mRNA decreased BP in SHR, but not in WKY. HR was not altered in either strain. Distribution of fluorescein-conjugated ODNs was detected in brain areas surrounding cerebral ventricles. 6. Our results indicate that the brain B1 receptor participates in the regulation of BP. Activation of the B1 receptor by kinin metabolites could participate in the pathogenesis of hypertension in SHR.

Original languageEnglish
Pages (from-to)1769-1776
Number of pages8
JournalBritish Journal of Pharmacology
Volume126
Issue number8
DOIs
Publication statusPublished - 1999

Fingerprint

Bradykinin B1 Receptors
Inbred SHR Rats
R 715
Blood Pressure
Oligodeoxyribonucleotides
Bradykinin
Brain
Kallidin
Cerebral Ventricles
Kinins
Injections
Captopril
Fluorescein
Tachycardia

Keywords

  • Brain
  • DNA
  • Fluorescence
  • Genetic
  • Hypertension
  • Kinins

ASJC Scopus subject areas

  • Pharmacology

Cite this

The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. / Emanueli, Costanza; Chao, Julie; Regoli, Domenico; Chao, Lee; Ni, Aiguo; Madeddu, Paolo.

In: British Journal of Pharmacology, Vol. 126, No. 8, 1999, p. 1769-1776.

Research output: Contribution to journalArticle

Emanueli, Costanza ; Chao, Julie ; Regoli, Domenico ; Chao, Lee ; Ni, Aiguo ; Madeddu, Paolo. / The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. In: British Journal of Pharmacology. 1999 ; Vol. 126, No. 8. pp. 1769-1776.
@article{7ec376288c894170bac5b3ec89e47074,
title = "The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats",
abstract = "1. We evaluated if the brain bradykinin (BK) B1 receptor is involved in the regulation of blood pressure (BP) in conscious rats. 2. Basal mean BP and HR were 115 ± 2 and 165 ± 3 mmHg and 345 ± 10 and 410 ± 14 beats min-1 in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR), respectively. Intracerebroventricular (i.c.v.) injection of 1 nmol B1 receptor agonist Lys-desArg9-BK significantly increased the BP of WKY and SHR by 7 ± 1 and 19 ± 2 mmHg, respectively. One nmol Sar[D-Phe8]-desArg9-BK, a kininase-resistant B1 agonist, increased the BP of WKY and SHR by 19 ± 2 and 17 ± 2 mmHg, respectively and reduced HR in both strains. 3. I.c.v. injection of 0.01 nmol B1 antagonists, LysLeu8-desArg9-BK or AcLys[D-βNal7,Ile8]-desArg9-BK (R715), significantly decreased mean BP in SHR (by 9 ± 2 mmHg the former and 14 ± 3 mmHg the latter compound), but not in WKY. In SHR, the BP response to R715 was associated to tachycardia. 4. I.c.v. Captopril, a kininase inhibitor, increased the BP of SHR, this response being partially prevented by i.c.v. R715 and reversed into a vasodepressor effect by R715 in combination with the B2 antagonist Icatibant. 5. I.c.v. antisense oligodeoxynucleotides (ODNs) targeted to the B1 receptor mRNA decreased BP in SHR, but not in WKY. HR was not altered in either strain. Distribution of fluorescein-conjugated ODNs was detected in brain areas surrounding cerebral ventricles. 6. Our results indicate that the brain B1 receptor participates in the regulation of BP. Activation of the B1 receptor by kinin metabolites could participate in the pathogenesis of hypertension in SHR.",
keywords = "Brain, DNA, Fluorescence, Genetic, Hypertension, Kinins",
author = "Costanza Emanueli and Julie Chao and Domenico Regoli and Lee Chao and Aiguo Ni and Paolo Madeddu",
year = "1999",
doi = "10.1038/sj.bjp.0702527",
language = "English",
volume = "126",
pages = "1769--1776",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats

AU - Emanueli, Costanza

AU - Chao, Julie

AU - Regoli, Domenico

AU - Chao, Lee

AU - Ni, Aiguo

AU - Madeddu, Paolo

PY - 1999

Y1 - 1999

N2 - 1. We evaluated if the brain bradykinin (BK) B1 receptor is involved in the regulation of blood pressure (BP) in conscious rats. 2. Basal mean BP and HR were 115 ± 2 and 165 ± 3 mmHg and 345 ± 10 and 410 ± 14 beats min-1 in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR), respectively. Intracerebroventricular (i.c.v.) injection of 1 nmol B1 receptor agonist Lys-desArg9-BK significantly increased the BP of WKY and SHR by 7 ± 1 and 19 ± 2 mmHg, respectively. One nmol Sar[D-Phe8]-desArg9-BK, a kininase-resistant B1 agonist, increased the BP of WKY and SHR by 19 ± 2 and 17 ± 2 mmHg, respectively and reduced HR in both strains. 3. I.c.v. injection of 0.01 nmol B1 antagonists, LysLeu8-desArg9-BK or AcLys[D-βNal7,Ile8]-desArg9-BK (R715), significantly decreased mean BP in SHR (by 9 ± 2 mmHg the former and 14 ± 3 mmHg the latter compound), but not in WKY. In SHR, the BP response to R715 was associated to tachycardia. 4. I.c.v. Captopril, a kininase inhibitor, increased the BP of SHR, this response being partially prevented by i.c.v. R715 and reversed into a vasodepressor effect by R715 in combination with the B2 antagonist Icatibant. 5. I.c.v. antisense oligodeoxynucleotides (ODNs) targeted to the B1 receptor mRNA decreased BP in SHR, but not in WKY. HR was not altered in either strain. Distribution of fluorescein-conjugated ODNs was detected in brain areas surrounding cerebral ventricles. 6. Our results indicate that the brain B1 receptor participates in the regulation of BP. Activation of the B1 receptor by kinin metabolites could participate in the pathogenesis of hypertension in SHR.

AB - 1. We evaluated if the brain bradykinin (BK) B1 receptor is involved in the regulation of blood pressure (BP) in conscious rats. 2. Basal mean BP and HR were 115 ± 2 and 165 ± 3 mmHg and 345 ± 10 and 410 ± 14 beats min-1 in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR), respectively. Intracerebroventricular (i.c.v.) injection of 1 nmol B1 receptor agonist Lys-desArg9-BK significantly increased the BP of WKY and SHR by 7 ± 1 and 19 ± 2 mmHg, respectively. One nmol Sar[D-Phe8]-desArg9-BK, a kininase-resistant B1 agonist, increased the BP of WKY and SHR by 19 ± 2 and 17 ± 2 mmHg, respectively and reduced HR in both strains. 3. I.c.v. injection of 0.01 nmol B1 antagonists, LysLeu8-desArg9-BK or AcLys[D-βNal7,Ile8]-desArg9-BK (R715), significantly decreased mean BP in SHR (by 9 ± 2 mmHg the former and 14 ± 3 mmHg the latter compound), but not in WKY. In SHR, the BP response to R715 was associated to tachycardia. 4. I.c.v. Captopril, a kininase inhibitor, increased the BP of SHR, this response being partially prevented by i.c.v. R715 and reversed into a vasodepressor effect by R715 in combination with the B2 antagonist Icatibant. 5. I.c.v. antisense oligodeoxynucleotides (ODNs) targeted to the B1 receptor mRNA decreased BP in SHR, but not in WKY. HR was not altered in either strain. Distribution of fluorescein-conjugated ODNs was detected in brain areas surrounding cerebral ventricles. 6. Our results indicate that the brain B1 receptor participates in the regulation of BP. Activation of the B1 receptor by kinin metabolites could participate in the pathogenesis of hypertension in SHR.

KW - Brain

KW - DNA

KW - Fluorescence

KW - Genetic

KW - Hypertension

KW - Kinins

UR - http://www.scopus.com/inward/record.url?scp=0033114049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033114049&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0702527

DO - 10.1038/sj.bjp.0702527

M3 - Article

C2 - 10372819

AN - SCOPUS:0033114049

VL - 126

SP - 1769

EP - 1776

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -